Microfluidic Immunocapture Device for Direct Detection of Lyme Disease

Lyme Disease is a multisystem infectious disease caused by the Borellia burgdorferi complex, and is a growing threat to public health. Approximately 476,000 people are infected with Lyme in the United States each year. Although Lyme is readily treated with antibiotics when detected early, early detection remains difficult. Current testing remains difficult because the standard 2-tiered ELISA/Western assay indirectly detects Lyme via measurement of a host immune response, which suffers from an inherent time-lag in host antibody production. A direct test for Lyme Disease would overcome these inherent limitations. To this end we report on the first microfluidic immunocapture device for Lyme Disease. We engineered a geometrically enhanced differential immunocapture (GEDI) technology to capture whole-organism Borrelia for direct on-chip detection. This approach is potentially amenable with other work in the field to develop direct PCR or aptamer tests for Lyme Disease, as our device could serve as a platform to drastically enhance the concentration of present Borrelia into a small volume.